SCHEMBL9853336

SCHEMBL9853336

CCCCCCCCCn1cnc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.68
SMN1; SMN2 Q16637 7/20 0.63
LMNA P02545 4/20 0.63
ALOX15 P16050 1/20 0.63
TSHR P16473 1/20 0.63
HTT P42858 4/20 0.61
MAPT P10636 3/20 0.61
STAT3 P40763 1/20 0.61
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
NPC1 O15118 1/20 0.55
NFKB1 P19838 1/20 0.55
RAB9A P51151 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
SLC9A1 P19634 2/20 0.54
EGLN3 Q9H6Z9 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
DRD2 P14416 1/20 0.52
DRD4 P21917 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9853294 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL3868979 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL595111 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL9038339 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL9038701 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL6321085 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL11408718 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL4888041 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL16097150 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL9853222 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109134549-A Iridium (III) complex and its preparation method and application for treating gastric cancer 广西中医药大学 2019-01-04 CN claimed
CN-108864202-A Compound and its preparation method and application for treating liver cancer 广西中医药大学 2018-11-23 CN claimed
WO-2024181373-A1 METHOD FOR SELECTIVELY MODIFYING SUBSTRATE SURFACE, METHOD FOR PRODUCING SURFACE-TREATED SUBSTRATE, AND COMPOSITION JSR株式会社 2024-09-06 WO disclosed
EP-4347544-A1 PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES Dow Technology Investments LLC (US) 2024-04-10 EP disclosed
CN-109563050-B Amide salt compound, catalyst for polyurethane production and method for producing polyurethane resin 广荣化学株式会社 2023-06-02 CN disclosed
CN-110475765-B Preparation method of amide compound 广荣化学株式会社 2023-04-07 CN disclosed
EP-3604287-B1 PRODUCTION METHOD FOR AMIDATE COMPOUND KOEI CHEMICAL CO (JP) 2022-08-03 EP disclosed
EP-3495353-B1 AMIDATE COMPOUND, CATALYST FOR POLYURETHANE PRODUCTION, AND METHOD FOR PRODUCING POLYURETHANE RESIN KOEI CHEMICAL CO (JP) 2021-11-17 EP disclosed
US-10913724-B2 Production method for amidate compound KOEI CHEMICAL COMPANY, LIMITED (JP) 2021-02-09 US disclosed
US-10689478-B2 Amidate compound, catalyst for polyurethane production, and method for producing polyurethane resin KOEI CHEMICAL COMPANY, LIMITED (JP) 2020-06-23 US disclosed
EP-3604287-A1 PRODUCTION METHOD FOR AMIDATE COMPOUND Koei Chemical Company, Limited (JP) 2020-02-05 EP disclosed
CN-110475765-A The preparation method of amides compound KOEI CHEMICAL CO 2019-11-19 CN disclosed
US-20190177464-A1 AMIDATE COMPOUND, CATALYST FOR POLYURETHANE PRODUCTION, AND METHOD FOR PRODUCING POLYURETHANE RESIN KOEI CHEMICAL COMPANY, LIMITED (JP) 2019-06-13 US disclosed
EP-3495353-A1 AMIDATE COMPOUND, CATALYST FOR POLYURETHANE PRODUCTION, AND METHOD FOR PRODUCING POLYURETHANE RESIN Koei Chemical Company, Limited (JP) 2019-06-12 EP disclosed
CN-109563050-A Amide salt compound, for the catalyst of polyurethane production and the production method of polyurethane resin 广荣化学工业株式会社 2019-04-02 CN disclosed
CN-109134549-A Iridium (III) complex and its preparation method and application for treating gastric cancer 广西中医药大学 2019-01-04 CN disclosed
CN-109134549-A Iridium (III) complex and its preparation method and application for treating gastric cancer 广西中医药大学 2019-01-04 CN disclosed
CN-108864202-A Compound and its preparation method and application for treating liver cancer 广西中医药大学 2018-11-23 CN disclosed
EP-0428383-A1 Process for surface treatment of copper and copper alloy SHIKOKU CHEMICALS CORPORATION (JP) 1991-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10913724-B2 Production method for amidate compound NAAA, PAM, CCKBR TDP1 4073/4885SMN1; SMN2 3643/4885LMNA 2972/4885
US-10689478-B2 Amidate compound, catalyst for polyurethane production, and method for producing polyurethane resin ARG1, NIT2, RER1 TDP1 1878/4885SMN1; SMN2 2448/4885LMNA 3140/4885
US-20190177464-A1 AMIDATE COMPOUND, CATALYST FOR POLYURETHANE PRODUCTION, AND METHOD FOR PRODUCING POLYURETHANE RESIN ARG1, NIT2, RER1 TDP1 1878/4885SMN1; SMN2 2448/4885LMNA 3140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.